Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T14352 |
Autotaxin-IN-1
|
PDE | Metabolism |
Autotaxin-IN-1 is a potent autotaxin inhibitor, which has favorable potency (IC50=2.2 nM), PK properties, and a robust PK/PD relationship and it is used in treatment of osteoarthritis pain[1]. | |||
T72837 | Autotaxin-IN-6 | ||
Autotaxin-IN-6 (compound 23),一种ATX (自分泌运动分子)抑制剂,具有30 nM的IC50值,能够减少细胞迁移,适用于抗癌研究。 | |||
T69647 |
UCM-05194
|
||
UCM-05194 is a potent Agonist of the Type 1 Lysophosphatidic Acid Receptor (LPA1). UCM-05194 Shows Efficacy in Neuropathic Pain Amelioration. UCM-05194 stands out as the most potent and selective LPA1 receptor agonist described so far (Emax = 118%, EC50 = 0.24 μM, KD = 19.6 nM; inactive at autotaxin and LPA2-6 receptors). | |||
T61612 |
ATX inhibitor 15
|
||
ATX inhibitor 15 (compound 30) is an indole-based carbamate derivative with a strong inhibitory effect on autotaxin (ATX), demonstrated by an IC50 of 2.17 nM. Additionally, ATX inhibitor 15 effectively inhibits ATX activity in vivo and suppresses the expression of pro-fibrotic genes. Furthermore, ATX inhibitor 15 exhibits protective effects in lung fibrosis induced by Bleomycin in mice [1]. | |||
T38000 |
Lysosphingomyelin (d18:1)
|
||
Sphingomyelins are complex membrane lipids composed of phosphorylcholine, sphingosine, and an acylated group, such as a fatty acid. Lysosphingomyelin is a naturally-occurring lipid which is produced by the removal of the acylated group of sphingomyelin by a deacylase. Lysosphingomyelin may, in turn, serve as a substrate for autotaxin, which removes choline to produce sphingosine-1-phosphate. The receptors and signaling pathways that are activated by lyso-sphingosine are diverse and vary between ... |